Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Key Takeaway: Alnylam Pharmaceuticals has announced that its management will present company overviews at two upcoming investor conferences. The Wells Fargo 21st Annual Healthcare Conference is scheduled for September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference will take place on September 14, 2026. Both events will feature live audio webcasts.
Price reaction · baseline $246.11 (2026-09-01 close) · hit pre-market · clean, no other ALNY news in the window
day 0 close · peak
+8.7%
day 1
+7.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam is actively engaging with investors.
  • The company is showcasing its RNAi therapeutics.
  • Upcoming presentations may enhance investor interest.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
• Wells Fargo 21stAnnual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts
• Morgan Stanley 24thAnnual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City
A live audio webcast of each presentation will be available on the Investors section of the Company’s website,www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on itsAlnylam 2030strategy to accelerate innovation and scale impact to transform human health. For more information, please visitwww.alnylam.comor follow Alnylam onX,LinkedIn,Facebook,Instagram, orYouTube.

Alnylam Pharmaceuticals, Inc.Bo Piela(Media)508-308-9783Josh Brodsky(Investors)617-551-8276

Frequently Asked Questions

When is Alnylam presenting at the Wells Fargo Conference?

Alnylam will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026.

Where will the Morgan Stanley Conference be held?

The Morgan Stanley 24th Annual Global Healthcare Conference will take place in New York City.

What is the focus of Alnylam's presentations?

Alnylam will provide overviews of its RNAi therapeutics during the presentations.

Will the presentations be available online?

Yes, there will be live audio webcasts of each presentation.

Last updated: Sep 2, 2026